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Dental pulp stem cells (DPSCs) are multipotent cells capable of differentiating into multiple cell lines, thus providing an alternative
source of cell for tissue engineering. Smooth muscle cell (SMC) regeneration is a crucial step in tissue engineering of the urinary
bladder. It is known that DPSCs have the potential to differentiate into a smooth muscle phenotype in vitro with differentiation
agents. However, most of these studies are focused on the vascular SMCs. The optimal approaches to induce human DPSCs
to differentiate into bladder SMCs are still under investigation. We demonstrate in this study the ability of human DPSCs to
differentiate into bladder SMCs in a growth environment containing bladder SMCs-conditioned medium with the addition of
the transforming growth factor beta 1 (TGF-𝛽1). After 14 days of exposure to this medium, the gene and protein expression of
SMC-specific marker (𝛼-SMA, desmin, and calponin) increased over time. In particular, myosin was present in differentiated cells
after 11 days of induction, which indicated that the cells differentiated into the mature SMCs. These data suggested that human
DPSCs could be used as an alternative and less invasive source of stem cells for smooth muscle regeneration, a technology that has
applications for bladder tissue engineering.
1. Introduction
Bladder augmentation or replacement is required in a variety
of urological disorders including cancer, spinal injury, and
benign bladder contracture.Hitherto, there is no suitable sub-
stitute available to restore the normal function of Detrusor
muscle of native bladder, which allows expansion for storage
of urine under low pressure (compliance) and contraction for
voiding. Augmentation cystoplasty to increase the bladder
capacity or substitution cystoplasty to replace the bladder
is currently performed using a piece of reconfigured bowel,
which has associated morbidity due to loss of contraction,
thus necessitating intermittent self-catheterization to empty
the bladder. There is mucous production and absorption of
electrolytes by the bowel mucosa, in addition to causing
infections, stones, and posing a small risk of cancer at
the bowel/bladder interface, thus making it far from an ideal
substitute. The ability to regenerate urological tissue with
functions similar to the native bladder tissue would be a step
forward in reducing the morbidity associated with the use of
bowel, thus providing a better quality of life for the patients.
Attempts have been made to construct an autologous
engineered bladder by obtaining urothelial and smooth
muscle cells from bladder biopsy, growing the cells in in
vitro cultures, and then seeding them onto a biodegradable
bladder-shaped scaffold before implanting in the patients [1].
However, functionally these reconstructed bladders do not
behave in the same way as the native bladder.
Although bladder smooth muscle cells (SMCs) are easy
to obtain by bladder biopsy, they do not show any useful
expansion in vitro [2, 3]; furthermore the cells obtained from
older individuals have a reduced capability for replication
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[3]. Therefore alternative cell sources are required for any
meaningful regeneration of urinary bladder tissue. Dental
pulp stem cells (DPSCs) are mesenchymal-derived stem cells
arising from the perivascular niche of dental pulp. Compared
with other mesenchymal stem cells (MSCs) derived from
bonemarrow, adipose tissue, peripheral blood, and umbilical
cord blood, DPSCs have marked advantage due to its acces-
sibility with least invasive procedures without any ethical
issues. Previous studies proved that DPSCs have potential for
odontogenic [4], endothelial [5], myogenic [6, 7], hepatocytic
[8], and melanocytic differentiation [9]. Due to this potential
versatility, DPSCs are considered to be multipotent stem cells
that can be used for a variety of therapeutic applications.
Previous studies has demonstrated that several lines of
undifferentiated mesenchymal stem cells (MSCs), such as
MSCs derived from adipose tissue [10] and bone marrow
[11], have already expressed the SMC markers such as alpha
smooth muscle actin (𝛼-SMA), desmin, and h1-calponin.
Belonging to one of MSCs, DPSCs could be another use-
ful precursor for SMC differentiation as they also share
certain SMC markers, for example, 𝛼-SMA. This has been
demonstrated to be upregulated when damage occurs to
the teeth, thus allowing regeneration [12]. Previous studies
have shown that there are various clones of DPSCs, some
losing their regenerative abilities faster than others. In this
study, we isolated and selected one of the human DPSCs
clones, which are able to maintain high proliferation abilities
over a long period of time, making them beneficial for
the future tissue engineering. Furthermore, bladder tissue
engineering so far has utilised a variety of stem cells including
those from embryo [13, 14], bone marrow [15], and adipose
tissue [10]. These stem cells have been differentiated into the
urothelial cells and smooth muscle cells, which make up the
layers of the urinary bladder. However, these cell sources
are associated with ethical problems, invasive procedure, or
inadequate expansion capability. The usage of human DPSCs
has the advantage of easy ethics approval and therefore
could potentially benefit more in the future application in
regenerative medicine.
It has been demonstrated that DPSCs have the potential
to differentiate into a smoothmuscle phenotype in vitro using
differentiation agents, and most of these studies are focused
on the vascular SMCs. However it is unclear whether human
DPSCs could be differentiated into bladder specific SMCs
in order to accommodate the urological functions in the
future regeneration medicine application. It is known that
cells release cytokines to neighbouring tissues, which can
modulate the fate of adjacent cells via paracrine signaling.
A coculturing method therefore is usually used in vitro to
induce stem cells to differentiate toward fully functional cells
when the induced growth factors are unknown. This study
aims to examine whether stem cells arising from the human
dental pulp can be induced to differentiate into bladder SMCs
by using the conditioned medium (CM) from bladder SMCs
and therefore have a potential clinical application in the tissue
engineering of urinary bladder. We present a reliable and
reproducible method of DPSCs differentiation into SMCs.
2. Materials and Methods
2.1. The Isolation of Human DPSCs Clone A32 and Human
SMCs. The clonal populations of DPSCs were isolated using
fibronectin based selection protocol as described previously
[16, 17]. Briefly, the pulp tissues were obtained from third
molars (donors aged from 17∼20 years) with the patient’s
informed consent and ethical approval by the South East
Wales Research Ethics Committee of the National Research
Ethics Service (permission number: 07/WESE04/84). Then
the pulp tissues were digested in a 4mg/mL solution of
collagenase/dispase (Roche Diagnostics) for 1 hour at 37∘C.
Following centrifugation and resuspension in alpha mod-
ification of Eagle’s medium (𝛼-MEM) supplemented with
100 units/mL penicillin, 100𝜇g/mL streptomycin, 20% (v/v)
heat-inactivated foetal bovine serum (FBS) (all Life Tech-
nologies), and 100 𝜇M l-ascorbic acid 2-phosphate (Sigma-
Aldrich), a single cell suspension was obtained by passing
through a 70𝜇m pore mesh cell strainer (BD Biosciences).
Cells were seeded at 4000 cells/cm2 onto 6-well culture
plates, previously coated with 10 𝜇g/mL fibronectin (Sigma-
Aldrich), and incubated at 37∘C in 5% CO
2
for 20 minutes.
The clones of cells that adhered to fibronectin were selected.
Following 12 days of culture, with medium changes every 2-
3 days, individual colonies detached using cloning rings and
accutase (Life Technologies). Single cell-derived clones were
expanded in culture by seeding at a density of 4000 viable
cells/cm2 on culture dishes of increasing surface area. The
level of population doublings (PD) during expansion culture
was monitored and the clone which could proliferate steadily
for up to 300 days of culture reaching 80+ PD was selected,
named A32:
PD =
log
10
(total cell count obtained) − log
10
(total cell count re-seeded)
log
10
(2)
. (1)
Human SMCs were obtained from the bladder of patients
who underwent open procedures for their bladder, after
patient consent and ethical approval by the South East
Wales Research Ethics Committee of the National Research
Ethics Service (permission number: 07/WESE04/84). The
human bladder tissue obtained was repeatedly washed with
phosphate buffered saline (PBS) supplemented with 1% peni-
cillin/streptomycin. Following this the bladder tissue was
incubated overnight on a petri dish in 1000U/mL dispase
2 (Roche) at 4∘C. After 12 hours the bladder tissue was
again washed repeatedly with PBS and the smooth muscle
layer separated from urothelial layer.The bladder muscle was
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minced into 1 × 1mm pieces and digested in collagenase
type IV enzyme 250 IU/mL (Sigma-Aldrich) for 30 minutes
at 37∘C. The cell suspension was sieved through a 70𝜇m
filter and suspended in Dulbecco’s modified Eagle’s medium
(DMEM), penicillin/streptomycin, and 10% FBS. The SMCs
were seeded in a flask at a density of 3000 cells/cm2. There-
after the SMCs were incubated at 37∘C in 5% CO
2
. After 24
hours the medium was changed and thereafter the medium
was changed every 2-3 days.
2.2. Differentiation of Human A32 DPSCs. Differentiation of
the A32 was induced by using CM collected from bladder
SMCs, supplemented with transforming growth factor beta
1 (TGF-𝛽1), similarly as previously described [15, 18, 19].
CM was obtained by culturing SMCs in DMEM and 10%
FBS until they reached passage 8. When they reached 70%
confluence the medium was changed to 𝛼-MEM and 15%
FBS. After 48 hours the medium was removed, centrifuged
at 1500 rpm for 5 minutes, and sieved through a 40𝜇L filter.
Initially various concentrations of CMwere used to ascertain
which were the most potent inducers of differentiation.
Concentrations of 0%, 10%, 20%, and 50% were trialled. It
was found that a concentration of 20% and 50% CM induced
the most differentiation of DPSCs to SMCs. Therefore 20%
CM was chosen as this required less passaging of SMCs to
retrieve the media. Many papers have used a protocol of
addition of growth factors (e.g., TGF-𝛽1) to media in order
to induce stem cells to differentiate into SMCs [15, 18, 19].
We chose TGF-𝛽1 at 2.5 ng/mL in DMEM and 15% FBS for
the SMC differentiation protocol based on our pilot titration
experiment. Previous studies also documented that addition
of L-ascorbic acid at 30 𝜇M works symbiotically with TGF-
𝛽1 [18]. However this did not appear to be the case in our
preliminary studies and therefore was excluded from the
protocol. Therefore it was decided to use 2.5 ng/mL TGF-
𝛽1 and 20% CM as an optimised SMCs differentiation pro-
tocol.
DPSCs were cultured with a 1 : 1 medium mixture con-
taining DMEM/15% FBS/20% CM, with the other DMEM
medium (15% FBS, 2.5 ng/mL TGF-𝛽1). Following the indi-
cated time (0, 5, 8, 11, and 14 days) of incubation, the mor-
phology, mRNA, and protein levels were evaluated compared
to SMCs and noninduced DPSCs, grown in their optimised
medium to assess their differentiation.
2.3. Immunocytochemistry. Cells were fixed with 4% PFA for
30min and then incubated in PBS containing 0.4% Triton X-
100 for 10min on ice and then blocked with bovine serum
albumin (BSA) for 60min at 37∘C.After the blocking step, the
cells were incubated with primary antibody, anti-vimentin
(1 : 100), anti-keratin (1 : 100), anti-STRO-1 (1 : 100), anti-
myosin (1 : 50), anti-alpha-SMA (1 : 100), and anti-desmin
(1 : 50) at 4∘C overnight; PBS was used as the negative
control. The cells were then washed with PBS and incu-
bated for 1 h with the secondary antibodies, namely, anti-
mouse IgG Alexa Fluor-488 or at anti-rabbit IgG Alexa
Fluor-594 1 : 1000 at room temperature. Glass cover slips
were mounted using mounting media supplemented with
DAPI stain (VectorLabs) and preparations imaged under a
fluorescent microscope.
2.4. Reverse Transcriptase PCR (RT-PCR) and Real Time
Quantitative PCR (qPCR). Total RNA was extracted from
the cells using an RNeasy Mini Kit (QIAGEN) according
to manufacturer’s directions. The total yield of RNA per
extraction was calculated using a Nanovue spectrophotome-
ter (GE Healthcare) to measure the absorbance at 260 nm.
A260/A280 ratios of 1.9–2.1 indicated extraction of good
quality RNA. CDNA was synthesised from 2000 ng RNA
using MMLV reverse transcriptase (Promega). PCR reac-
tions were performed on DPSCs using GoTaq Polymerase
(Promega) and the product specific primers CD105, CD73,
CD44, CD90, and CD34 listed in Table 1 under the following
cycling conditions: 1 minutes denaturation at 95∘C followed
by 1 minutes annealing at 60∘C and 1.5 minutes elongation at
72∘C for 30 cycles.The housekeeping gene D-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as positive
control. PCR products were visualized under UV light fol-
lowing electrophoresing in 1.4% (w/v) agarose/TAE gel.
For qPCR readings, three separate cDNA samples were
used and each measured in triplicate. Target-specific primers
(Table 1) were added to each cDNA sample together with Pre-
cisionMasterMixwith ROX and SYBRgreen (PrimerDesign).
Readings were taken using an ABI Prism fast 7500 qPCR
machine (Advanced Biosystems) under the following cycling
conditions: an initial denaturation step of 95∘C for 2 minutes
followed by 40 cycles of 15 seconds denaturation (95∘C) and
1 minute annealing/elongation at 60∘C. The relative amount
or fold change of the target gene expression was normalized
relative to the level of GAPDH and relative to a control (non-
induced cells).
2.5. Western Blot Analysis. The total protein content was
extracted from the cells by using lysis buffer containing
protease inhibitors (Sigma-Aldrich, USA). The protein con-
centration was measured by using a BCA-200 protein assay
kit (Pierce, Rockford Ill., USA). Equal amounts of protein
were separated by sodiumdodecyl sulfate/polyacrylamide gel
electrophoresis and transferred to a polyvinylidene fluoride
membrane (PVDF). The membrane was blocked in TRIS-
buffered saline with Tween (TBST) containing 5% nonfat
dry milk for 2 h and probed with primary antibodies myosin
(1 : 500, Sigma), 𝛼-SMA (1 : 500, Sigma), desmin (1 : 500,
Sigma), and GAPDH (1 : 1000, Sigma) overnight at 4∘C
and then incubated for 2 h with a horseradish-peroxidase-
conjugated anti-mouse IgG antibody or anti-rabbit IgG
diluted 1 : 20,00 (Sigma). Protein bands were visualized on
X-ray film by using an enhance chemiluminescence system
(GE Healthcare, Buckinghamshire, UK). The relative protein
expression intensities were quantified by densitometry by
using Quantity One analysis software.
2.6. Statistical Analysis. Each experiment was performed
at least three times, unless otherwise indicated. Data are
reported as the mean ± SE (standard error) deviation from
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Table 1
Genes Forward and reverse primers Accession number
GAPDH 5
󸀠-GCACCGTCAAGGCTGAGAAC-3󸀠 NM 002046.3
5󸀠-TGGTGAAGACGCCAGTGGA-3󸀠
CD105 5
󸀠-GAAACAGTCCATTGTGACCTTCAG-3󸀠 NM 001114753.2
5󸀠-GATGGCAGCTCTGTGGTGTTGACC-3󸀠
CD73 5
󸀠-GTCGCGAACTTGCGCCTGGCCGCCAAG-3󸀠 NM 001204813.1
5󸀠-TGCAGCGGCTGGCGTTGACGCACTTGC-3󸀠
CD44 5
󸀠-CATCTACCCCAGCAACCCTA-3󸀠 NM 000610.3
5󸀠-CTGTCTGTGCTGTCGGTGAT-3󸀠
CD90 5
󸀠-ATGAACCTGGCCATCAGCATCG-3󸀠 NM 006288.3
5󸀠-CACGAGGTGTTCTGAGCCAGCA-3󸀠
CD34 5
󸀠-ACAGGAGAAAGGCTGGGCGAAGACCCT-3󸀠 NM 001025109.1
5󸀠-TCCCCTGGGGGTTCCTGTATTGCGGCA-3󸀠
𝛼-SMA (ACTA2) 5
󸀠-CCGGTTGGCCTTGGGGTTCAGGGGTGCC-3󸀠 NM 001141945.1
5󸀠-TCTCTCCAACCGGGGTCCCCCCTCCAGCG-3󸀠
Myosin (MYH11) 5
󸀠-AAGAAAGACACAAGTATCACGGGAGAGC-3󸀠 NM 001040113.1
5󸀠-TGTCACATTAATTCCCATGAGGTGGCAA-3󸀠
Desmin 5
󸀠-CACCATGAGCCAGGCCTACTCGTCCA-3󸀠 NM 001927.3
5󸀠-GGCAGCCAAATTGTTCTCTGCTTCTTCC-3󸀠
Calponin 5
󸀠-GGCTCCGTGAAGAAGATCAATGAGTCAA-3󸀠 NM 001299.4
5󸀠-CCCTAGGCGGAATTGTAGTAGTTGTGTG-3󸀠
three independent experiments.The significance of the differ-
ences between the experimental and the control groups was
determined by using one-way analysis of variance; 𝑃 < 0.05
indicated statistical significance.
3. Results
3.1. Isolation and Characterization of DPSC Clone A32.
Dental pulp cells were successfully isolated from pulp tis-
sue of extracted third molars. The clones of cells that
adhered to fibronectin were selected. Single cell-derived
clones were expanded in culture by seeding at a density of
4000 viable cells/cm2 on culture dishes of increasing surface
area. The clone, which could proliferate steadily for up to
300 days of culture reaching 80+ PD, was selected, named
A32 (Figure 1(a)). Then A32 was characterized by Rt-PCR,
immunocytochemical staining, and multiple lineage differ-
entiation tests. The result of Rt-PCR showed that A32 were
found to express a range of mesenchymal stem cell markers
including CD105, CD73, CD44, and CD90 but not to express
the marker of CD34 (Figure 1(b)). Immunocytochemical
staining of A32 revealed that the cells positively expressed
vimentin (Figure 1(c)) and STRO-1 (Figure 1(d)) and were
negative for keratin expression (Figure 1(e)). The multiple
lineage differentiation tests revealed that A32 stained positive
for lipid droplets with oil-red o after 5 weeks of adipogenic
induction (Figure 1(f)). After 3 weeks of osteogenic induction
and chondrogenic induction,A32 stained positive formineral
nodules with alizarin red S (Figure 1(g)) and chondrogenic
with safranin o S (Figure 1(h)).
3.2. Change in Cell Morphology after SMC-Induction. The
A32 were cultured in the differentiation medium for 14 days.
The morphology of A32 was changing according to the time
course (Figures 2(a)–2(e)). After 11 days, most of the cells
began to display the typical “hill and valley” (Figure 2(d))
compared with the morphology of SMCs (Figure 2(f)). Cells
in the control group maintained the spindle shape character-
istic to DPSCs (Figure 2(a)).
3.3. Expression of Main SMCs Markers Using Immunocyto-
chemistry. Noninduced A32 were found to express 𝛼-SMA
(Figure 3(d)) and desmin (Figure 3(f)) already, but none of
these cells stained positive for myosin (Figure 3(e)). The
expression of 𝛼-SMA and desmin appeared to increase with
the cells cultured in the differentiation medium over time.
The pictures of 11 days differentiation are shown (Figures 3(g)
and 3(i)). The differentiated cells stained positive for myosin
after 11 days of induction (Figure 3(h)). The SMCs staining
positive for𝛼-SMA,myosin, and desminwere regarded as the
positive control (Figures Figures 3(a)–(c)).
3.4. The Expression of SMC-Specific Markers in Differentiated
A32. The time course (0 d, 5 d, 8 d, 11 d, and 14 d) to detect
myosin, 𝛼-SMA, desmin, and calponin mRNA expression
in A32 in response to the induction of the differentiation
medium was performed. The mRNA expression of 𝛼-SMA
(Figure 4(a)) and calponin (Figure 4(d)) appeared to increase
over time.ThemRNA expression ofmyosin (Figure 4(b)) and
desmin (Figure 4(c)) increased after 11 days of differentiation
and maintained their maximal induction until 14 days.
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Figure 1: Characterization of human dental pulp stem cells (DPSCs) clone A32. The population doublings of DPSCs clone A32 exceed 80+
over 300 days in culture (a). The characterization of A32 by Rt-PCR and immunocytochemical staining: positive for the markers of CD105,
CD73, CD44, and CD90 (b), negative for the marker of CD34 (b), positive immunostaining for vimentin (c) and STRO-1 (d), and negative
immunostaining for keratin (e). This clone was able to differentiate into the 3 mesenchymal lineages: adipogenic (oil-red o staining) (f),
osteogenic (alizarin red staining) (g), and chondrogenic (safranin o staining) (h) when cultured in appropriate differentiation conditions in
vitro compared to control groups ((i)–(k)), respectively.
The mRNA expression of SMCs was regarded as the positive
control. The protein level of myosin, 𝛼-SMA, and desmin
was analysed by western blotting.The protein level of myosin
began to increase after 8 days of induction and reached its
maximal induction at 14 days (Figures 4(e) and 4(f)). The
protein level of desmin (Figures 4(e) and 4(g)) and 𝛼-SMA
(Figures 4(e) and 4(h)) appears to increase over time after
SMC-induction.They reached their highest level after 14 days
of induction.The protein expression of SMCswas regarded as
the positive control.
4. Discussion
The urinary bladder wall is composed of Detrusor smooth
muscle arranged in three distinct layers responsible for
its compliance to store urine under low pressure and
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Figure 2: Morphology changes of human dental pulp stem cell (DPSC) clone A32 following an SMC-induction protocol. The morphology is
demonstrated to change from the spindle shape of the A32 to the “hill and valley” morphology of SMCs over time ((a)–(e)). The SMC as the
positive control (f). The noninduced A32 as the negative control (a). Bar 50 𝜇m.
contraction for voiding, lined by a layer of transitional cells
that provide a barrier to absorption. For many patients
requiring augmentation or removal of the bladder, a piece
of bowel is used. This however does not provide the same
function as the native bladder, and there is much associated
morbidity. Tissue engineering to generate the bladder wall
components with properties similar to native tissues will
provide a solution to this problem. Many advances have been
made in tissue engineering of the urinary bladder using stem
cell technology. Previous studies obtained autologous SMCs
directly from the bladder muscle biopsy. However, it poses
many experimental challenges, apart from the clinical need
of invasive procedures to obtain a biopsy. It is extremely
difficult to establish a sufficiently healthy cell population
when obtained by biopsies from patients with end-stage
bladder disease or from older individuals who are the most
likely candidates requiring such bladder replacement or
augmentation [3].
Additionally, patients with bladder tumours cannot use
their own SMCs, due to the high potential of tumour
cells contamination. Numerous investigators have tried to
find alternative source of stem cells that can be induced
to differentiate into the SMCs to replace the autologous
SMCs. Differentiation protocols using cells from adipocytes
[10], embryonic cells [13, 14], bone marrow [15], and urine
[19] have been described for bladder tissue engineering
experiments. Hitherto, none of the studies have assessed the
potential of humanDPSCs differentiating into bladder SMCs.
Compared with the above-mentioned sources of cells, DPSCs
demonstrated advantages of easy access with least invasive
procedures, without ethical issues, high proliferation, excel-
lent regeneration, and multiple-potential of differentiation as
well as little inherent immunogenicity, establishing DPSCs as
a promising cell source for the tissue engineering and regen-
erativemedicine experiments.The differentiation potential of
DPSCs is not limited to mesenchymal cell type only; there
is evidence of differentiation potential for endothelial [5],
myogenic [6, 7], hepatocytic [8], and melanocytic routes
[9]. Therefore, the potential clinical application of DPSCs is
not only in regenerative dentistry, but also in regenerative
treatments for other systems [20], such as neuroplasticity
for central nerve disease [21–23] and spinal cord injury
[24], myogenic regeneration for muscular dystrophy and
myocardial infractions [5, 25], and osteogenic regeneration
for calvarial bone [26, 27], mandibular bone [28, 29], and
alveolar bone [30]. Additionally, DPSCs have been proved to
be tolerated as an allogeneic cell transplant without the need
for immunosuppression, consequently bypassing the issue of
patient-matched autologous applications [31]. The clone of
A32 that we isolated from a number of clones of human
DPSCs is particularly versatile. It not only has potential to
differentiate into all three mesenchymal lineages but also
expressed the SMC-related markers including 𝛼-SMA and
desmin, indicating its potential to differentiate into SMCs.
One of the most important advantages of A32 is its high
proliferation capacity for up to 300 days of culture (80+
PD), which makes it more valuable for tissue engineering.
We demonstrated in this study that the DPSCs clone A32
can be induced to differentiate into bladder SMCs using a
human bladder SMCs-CMmodel in combination with TGF-
𝛽1, demonstrated by the “hill and valley” morphology change
after 11 days of induction, and confirmed by 𝛼-SMA, desmin,
myosin, and calponin expression. We further found that 𝛼-
SMA was already present in noninduced DPSCs, which is
similar to findings in human bone marrow mesenchymal
stem cells (BMMSCs) and human adipose-derived stem cells
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Figure 3: Immunocytochemistry ofmain SMCsmarkers in human dental pulp stem cell (DPSC) cloneA32 after SMC-induction.The induced
cells were stained for the SMCs markers of 𝛼-SMA, myosin, and desmin for 11 d ((g)–(i)). Noninduced A32 as the negative control ((d)–(f)).
The SMCs as the positive control ((a)–(c)). The green staining indicates a positive result. Nuclei were stained with DAPI. Bar 50 𝜇m.
[15], but not in human embryonic stem cells [13]. It was
upregulated when the cells were differentiated. 𝛼-SMA is
an early marker of developing smooth muscle, which does
not provide definitive evidence for a smooth muscle lin-
eage. Thus, to further characterize myogenic differentiation
thoroughly, we chose to evaluate not only 𝛼-SMA but also
other smooth muscle markers, particularly myosin which is
not detected in any other cell type and is only expressed in
contractile SMCs [32, 33]. The expression of myosin was not
seen in the noninduced DPSCs and early stage of induction
but was present after 11 days of differentiation, indicating the
differentiation into the mature SMCs. Desmin is a muscle-
specific intermediate filament that plays an important role in
integrating the sarcolemma, Z disk, and nuclear membrane
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Figure 4: The expression of SMCs markers in human dental pulp stem cell (DPSC) clone A32 after SMC-induction. The A32 were induced
in the SMCs induction protocol of 20% conditioned medium and 2.5 ng/mL TGF-𝛽1 for the indicated time (0 d, 5 d, 8 d, 11 d, and 14 d). SMCs
were regarded as a positive group. Noninduced A32 was regards as negative control. The mRNA expression of 𝛼-SMA, myosin, desmin, and
calponin was analysed by qRT-PCR ((a)–(d)) and the protein levels of 𝛼-SMA, myosin, desmin were analysed by western blotting (e). The
relative band intensities were determined by densitometry ((f)–(h)). Statistical analysis was performed by using one-way ANOVA. Date are
shown as means ± SE. ∗𝑃 < 0.05 when compared with the 0D group.
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in sarcomeres and regulating sarcomere architecture [34].
The stem cells derived from embryonic cells [13], adipocytes
[10], and urine [19] cannot express desmin at both gene and
protein levels before differentiation. Interestingly, the expres-
sion of desmin demonstrated low basal level in noninduced
DPSCs, which indicates DPSCs may be more suitable to be
induced into SMCs for bladder tissue regeneration.
Belonging to the TGF-𝛽 family, TGF-𝛽1 is deemed as
a multifunctional growth factor, which regulates a wide
range of biological processes, including cell proliferation, cell
survival, and cell differentiation as well as cell migration [35,
36]. Studies have demonstrated that TGF-𝛽1 plays a pivotal
role inmultilineage differentiation of mesenchymal stem cell.
It promotes chondrogenic and osteogenic differentiation of
BMMSCs [37–39], while it inhibits adipogenic differentiation
of BMMSCs [39]. The effect of TGF-𝛽1 for MSC differ-
entiation involves all three lineages, which contributes to
the development of SMCs from both embryonic stem cells-
derivedmesenchymal cells (ES-MCs) [13] and BMMSCs [15].
Gong and Niklason [40] also showed that TGF-𝛽1 could
inhibit MSC proliferation but increased the expression of
calponin in a dose-dependent manner, which indicate that
TGF-𝛽1 not only initiates SMCs differentiation but also pro-
motes further differentiation. TGF-𝛽1-mediated SMCs differ-
entiation was demonstrated throughmultiple signaling path-
ways, including Smad, p38 MAPK, and PI3K signaling [41].
In in vitro model system for vascular smooth muscle differ-
entiation from human ES-MCs, TGF-𝛽1 induced expression
of SMCs markers depending on Smad [41], Jagged1-Notch
[42], and PI3K signaling [41], as well as serum response factor
(SRF)/CArG/myocardin [41], because either downregulation
of Smad2, Smad3, and SRF or use of signaling inhibitors
of Notch or PI3K blocks the expression of SMC markers.
Additionally, both ERK/MAPK [43, 44] and Jagged1-Notch
signaling [45] are involved in regulating the differentiation
of BMMSCs into vascular SMCs. However, most of previous
studies investigating the potential signaling pathways are
mainly focused on the differentiation of vascular SMCs from
ES-MCs and BMMSCs, and the control mechanism of the
bladder SMCs differentiation from human DPSCs remains
unknown. The PI’s lab has recently discovered that Wnt-
mediated GSK3𝛽/𝛽-catenin signaling was required in the
process of human DPSCs towards human bladder SMCs
(unpublished data).Therefore, further in-depth investigation
shall be performed to fully evaluate the control mechanism of
Wnt pathway during bladder SMCs differentiation, as well as
the crosstalk between multiple pathways regulated by TGF-
𝛽1.
Smooth muscle is an involuntary nonstriated muscle
which can be found in most parts of human organs. Among
them, one ofmost important smoothmuscleswithin thewalls
of blood vessels is specifically called vascular smooth muscle,
which is mainly in the tunica media layer of the arterioles
and veins. Apart from that, it also can be found in lymphatic
vessels, the urinary bladder, uterus (termed uterine smooth
muscle),male and female reproductive tracts, gastrointestinal
tract, respiratory tract, arrector pili of skin, the ciliarymuscle,
and iris of the eye. Although SMCs within different organs
might have similar morphological structure, their functions
can be distinctively different depending on the hosting organs
in which the SMCs are located. For example, SMCs in
the stomach and intestines are responsible for propelling
food through the digestive tract; SMCs in the vessels are
responsible for the maintenance of normal blood pressure,
whilst SMCs in the urinary bladder are responsible for storing
urine and contraction for voiding. Therefore, in order to
perform individual functions in different organs, SMCs tend
to differentiate in an organ specific manner, determined by
the individual niche accommodating the cells. Previous study
has reported that BMMSCs can be induced to differentiate
into vascular SMCs for vascular remodeling and repair after
vascular injury, by conditioning them with vascular SMCs.
Additionally, MSCs derived from bone marrow [46], dental
pulp [47], and adipose tissue [48] have been regarded as
promising candidates in the cell based therapies for muscle
regeneration in muscular dystrophy patients, by coculturing
them with skeletal myoblasts. The DPSCs/bladder SMCs
coculturing protocol proposed in this study therefore can
be a useful approach to differentiate toward bladder specific
SMCs with potential urological functions. In our study,
both TGF-𝛽1 and conditionedmedium derived from bladder
SMCs are required for bladder SMCs differentiation. Previous
study showed that several cytokines/growth factors including
PDGF-BB, TGF-𝛽1, HGF, and VEGF were detected in the
SMCs-CM [15]. HGF/VEGF were expressed in high levels
at the later stage of differentiation [15]. Further clarification
is desired to fully reveal the synergistic and interactive
functions of these growth factors in the regulation of bladder
specific SMCs differentiation.
5. Conclusion
This study demonstrates that DPSCs can be induced to
differentiate into bladder associated SMCs when treated with
a combination of CM from bladder SMCs and TGF-𝛽1. The
multipotency and high proliferation of A32 along with its
ability to differentiate into bladder SMCs are demonstrated
for the first time. More work is required to investigate the
related signaling pathways controlling the bladder SMCs
differentiation and to evaluate the function of DPSCs dif-
ferentiated bladder SMC-like cells after transplantation in
vivo. This study represents a step forward in providing a
promising alternative source of cells that are obtained by least
invasive procedure without ethical issues, for future research
in urinary bladder tissue engineering.
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